These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26558734)

  • 1. Safety of rilpivirine and boceprevir coadministration in HIV-infected patients treated for acute hepatitis C virus infection.
    Hullegie SJ; de Winter BC; Posthouwer D; Koopmans PP; Claassen MA; Burger DM; Rijnders BJ
    AIDS; 2016 Jan; 30(3):529-30. PubMed ID: 26558734
    [No Abstract]   [Full Text] [Related]  

  • 2. Boceprevir, telaprevir, and rilpivirine hydrochloride.
    Hussar DA; Snell CW
    J Am Pharm Assoc (2003); 2012; 52(1):120-6. PubMed ID: 22257626
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
    Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
    Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis drug reduces effects of HIV medications.
    Kuehn BM
    JAMA; 2012 May; 307(20):2138. PubMed ID: 22618906
    [No Abstract]   [Full Text] [Related]  

  • 5. [Boceprevir and telaprevir: clinical efficacy, safety and drug-drug interactions].
    Nikitin AV
    Antibiot Khimioter; 2012; 57(9-10):47-9. PubMed ID: 23477220
    [No Abstract]   [Full Text] [Related]  

  • 6. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
    Butt AA; Kanwal F
    Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
    Seden K; Back D
    Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers.
    Mora-Peris B; Else L; Goldmeier D; Mears A; Weston R; Cooke G; Khoo S; Back D; Winston A
    J Antimicrob Chemother; 2015; 70(6):1812-5. PubMed ID: 25693997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail.
    Charlton M
    Hepatology; 2011 Jul; 54(1):3-5. PubMed ID: 21710471
    [No Abstract]   [Full Text] [Related]  

  • 11. Boceprevir: serious haematological disorders.
    Prescrire Int; 2014 Oct; 23(153):242. PubMed ID: 25969852
    [No Abstract]   [Full Text] [Related]  

  • 12. Syncope during boceprevir treatment in hepatitis C.
    Ridruejo E; Silva MO; Mandó OG
    Ann Hepatol; 2013; 12(5):837-8. PubMed ID: 24018506
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythema Annulare Centrifugum in the Era of Triple Therapy With Boceprevir Plus Pegylated Interferon α-2b and Ribavirin for Hepatitis C Virus Infection.
    di Meo N; Stinco G; Fadel M; Errichetti E; Trevisan G
    J Cutan Med Surg; 2015; 19(3):203-4. PubMed ID: 26060126
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.
    Lamers MH; Broekman MM; Boucher CA; Brouwer JT; Burger DM; van Hoek B; Hoepelman AI; de Knegt RJ; Reesink HW; Drenth JP; ; ;
    Neth J Med; 2013 Sep; 71(7):377-85. PubMed ID: 24038567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
    Poizot-Martin I; Bellissant E; Garraffo R; Colson P; Piroth L; Solas C; Renault A; Bourlière M; Halfon P; Ghosn J; Alric L; Naqvi A; Carrieri P; Molina JM;
    HIV Clin Trials; 2016 Mar; 17(2):63-71. PubMed ID: 27077673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole.
    de Kanter CT; Colbers AP; Blonk MI; Verweij-van Wissen CP; Schouwenberg BJ; Drenth JP; Burger DM
    J Antimicrob Chemother; 2013 Jun; 68(6):1415-22. PubMed ID: 23429642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
    Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
    AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of boceprevir for hepatitis C.
    Neoh CF; Kong DC
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):319-34. PubMed ID: 24708054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
    Venkatraman S
    Trends Pharmacol Sci; 2012 May; 33(5):289-94. PubMed ID: 22521415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First case of drug rash eosinophilia and systemic symptoms due to boceprevir.
    Samain A; Duval-Modeste AB; Joly P; Leblanc C; Massy N; Courville P; Goria O; Riachi G
    J Hepatol; 2014 Apr; 60(4):891-3. PubMed ID: 24333861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.